Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis (Q37033874)

17 August 2017

1 reference

title

Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. (English)

1 reference

17 August 2017

1 reference

Ryuji Koike

1

1 reference

17 August 2017

Tsutomu Takeuchi

2

1 reference

17 August 2017

Katsumi Eguchi

3

1 reference

17 August 2017

Nobuyuki Miyasaka

4

1 reference

17 August 2017

Japan College of Rheumatology

5

1 reference

17 August 2017

20 December 2007

1 reference

17 August 2017

1 reference

17 August 2017

17

1 reference

17 August 2017

6

1 reference

17 August 2017

451-458

1 reference

Guidelines for the management of rheumatoid arthritis: 2002 Update

17 August 2017

1 reference

https://api.crossref.org/works/10.3109%2FS10165-007-0626-3

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-007-0626-3

Japan deaths spark concerns over arthritis drug

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-007-0626-3

Mycobacterium abscessus infection after use of tumor necrosis factor alpha inhibitor therapy: case report and review of infectious complications associated with tumor necrosis factor alpha inhibitor use.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-007-0626-3

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-007-0626-3

Predictors of infection in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-007-0626-3

Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-007-0626-3

Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-007-0626-3

BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-007-0626-3

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-007-0626-3

Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-007-0626-3

Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-007-0626-3

Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-007-0626-3

Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-007-0626-3

Record linkage to conduct an epidemiologic study on the association of rheumatoid arthritis and lymphoma in the Province of Saskatchewan, Canada.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-007-0626-3

Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-007-0626-3

Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-007-0626-3

Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-007-0626-3

Pregnancy outcome in women who were exposed to anti–tumor necrosis factor agents: Results from a national population register

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-007-0626-3

Rheumatoid arthritis and cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-007-0626-3

10.3109/S10165-007-0626-3

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference